Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastien A Burel

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Nucleic Acid Therapeutics|May 26, 2017
Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman PrimatesScott P Henry, Padmakumar Narayanan, Lijiang Shen, et al.
Nucleic Acid Therapeutics|November 10, 2022
Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Through TLR9 in Human Burkitt Lymphoma B Bjab CellsAdam J Pollak, Patrick Cauntay, Todd Machemer, et al.
Nucleic Acid Therapeutics|August 17, 2022
Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear CellsSebastien A Burel, Todd Machemer, Brenda F Baker, et al.
Clinical and Translational Science|January 11, 2023
Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse eventsWesley Partridge, Sebastien A Burel, Annie Ferng, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2004
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia developmentMing Yan, Sebastien A Burel, Luke F Peterson, et al.
Nucleic Acid Therapeutics|August 2, 2019
Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-<i>O</i>-Methoxyethyl Antisense OligonucleotideElaine Pirie, Patrick Cauntay, Wuxia Fu, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 17, 2012
Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon responseSebastien A Burel, Todd Machemer, Frank L Ragone, et al.
Toxicologic Pathology|December 27, 2018
Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 MiceTae-Won Kim, Chris N Papagiannis, Laura S Zwick, et al.
Nucleic Acid Therapeutics|February 6, 2025
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry RecommendationsPatrik Andersson, Sebastien A Burel, Heather Estrella, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 1, 2016
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersStanley T Crooke, Brenda F Baker, T Jesse Kwoh, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Nucleic Acid Therapeutics|May 26, 2017
Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman PrimatesScott P Henry, Padmakumar Narayanan, Lijiang Shen, et al.
Nucleic Acid Therapeutics|November 10, 2022
Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Through TLR9 in Human Burkitt Lymphoma B Bjab CellsAdam J Pollak, Patrick Cauntay, Todd Machemer, et al.
Nucleic Acid Therapeutics|August 17, 2022
Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear CellsSebastien A Burel, Todd Machemer, Brenda F Baker, et al.
Clinical and Translational Science|January 11, 2023
Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse eventsWesley Partridge, Sebastien A Burel, Annie Ferng, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2004
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia developmentMing Yan, Sebastien A Burel, Luke F Peterson, et al.
Nucleic Acid Therapeutics|August 2, 2019
Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-<i>O</i>-Methoxyethyl Antisense OligonucleotideElaine Pirie, Patrick Cauntay, Wuxia Fu, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 17, 2012
Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon responseSebastien A Burel, Todd Machemer, Frank L Ragone, et al.
Toxicologic Pathology|December 27, 2018
Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 MiceTae-Won Kim, Chris N Papagiannis, Laura S Zwick, et al.
Nucleic Acid Therapeutics|February 6, 2025
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry RecommendationsPatrik Andersson, Sebastien A Burel, Heather Estrella, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 1, 2016
Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersStanley T Crooke, Brenda F Baker, T Jesse Kwoh, et al.
Pageof 2